Business Wire

The University of California, Berkeley Partners with NTT to Accelerate Smart Technologies

19.5.2020 01:00:00 EEST | Business Wire | Press release

Share

The University of California, Berkeley and NTT Corporation (NTT) today announced a connected campus pilot project that will leverage technology to transform the UC Berkeley Parking and Transportation Department by analyzing patterns, easing traffic congestion and increasing pedestrian safety in the Bancroft Way area of campus.

The pilot will incorporate NTT’s Accelerate Smart data platform and Dell Technologies’ modular data center infrastructure for edge deployments of high-definition optical sensors and IoT devices that monitor traffic-related issues. These smart technologies will provide data to facilitate enhanced traffic management and mobility. As a first step in their “Connected Campus” initiative, UC Berkeley will leverage vehicle counting and classification to make informed decisions and develop specific solutions.

“At Berkeley, we are always trying to stay on top of emerging trends in parking and transportation, and by incorporating smart technologies, our campus can serve as a test bed for new technologies that can be put into operation immediately,” said Seamus Wilmot, Director of Parking and Transportation, UC Berkeley. “Our partnership with NTT and Dell Technologies makes us more digitally-enabled and provides a better understanding for alleviating the root causes of traffic issues. These technologies will help us solve how to manage the curb space at an area that has been challenging for our students, faculty, staff and partners.”

As part of the pilot, NTT and Dell Technologies will implement smart IoT, safety and security innovations that support UC Berkeley’s Parking and Transportation Department, such as real-time alerts and traffic statistics that improve predictions and outcomes. With quantifiable data, UC Berkeley can curb congestion caused by events, ride share traffic, delivery vehicles and transit operations.

The pilot program is designed to provide automated deployment and operation of necessary information and communications technology (ICT) resources from devices and networks to the cloud. The solution will ensure UC Berkeley can focus on improving traffic conditions through analysis and process more efficiently without worrying about ICT deployment and optimization issues.

“This traffic management pilot program begins UC Berkeley’s transformation to a Connected Campus,” said Akira Shimada, Senior Executive Vice President, NTT. “Connected Campuses of the future will offer endless possibilities—for safety, crowd control, traffic and facilities management. UC Berkeley is just getting started, but as a world renowned forward-thinking academic and research University, they see the potential to improve the campus experience and operations using data and smart technologies.”

NTT, along with its operating companies, will deploy its Accelerate Smart solution, which is a secure, distributed network as a platform solution built on NTT’s innovative Cognitive Foundation™ architecture. It enables remote creation, management and operation of information and communications technology resources, from devices and networks to the cloud. It also incorporates hyperconverged infrastructure and IoT gateways from Dell Technologies, as well as virtualization software hosting predictive analytics applications from VMware.

“When we leverage longstanding relationships with great partners like NTT, our joint customers can transform the way they do business,” said Denise Millard, Senior Vice President, Global Alliances, Dell Technologies. “Together we are able to provide customers like UC Berkeley with new tools to leverage data in meaningful ways and make decisions faster to ultimately improve the experience of those on campus.”

Following the initial pilot, UC Berkeley, NTT and Dell Technologies plan to evaluate viability to extend the pilot and potentially add additional locations and use cases on campus. To learn more about the NTT accelerating smart solutions, visit NTT DATA’s website and watch the Accelerate Smart case study with the city of Las Vegas on YouTube.

About NTT

NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.

As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Drew Wilson, NTT DATA Services
drew.wilson@nttdata.com
469.486.8653

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release

Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release

ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye